dm-ИДС
sa farmavet - hipoclorură де sodiu, hidroxid де potasiu - dezinfectant
sandostatin lar 10 mg pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită
novartis pharma ag - octreotidum - pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită - 10 mg
sandostatin lar 20 mg pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită
novartis pharma ag - octreotidum - pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită - 20 mg
sandostatin lar 30 mg pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită
novartis pharma ag - octreotidum - pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită - 30 mg
verzenios
eli lilly nederland b.v. - abemaciclib - sânii neoplasme - agenți antineoplazici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - alte medicamente pentru sistemul nervos - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
zometa solutie perfuzabila 4 mg/100 ml
novartis pharma ag - acid zoledronicum - solutie perfuzabila - 4 mg/100 ml
zometa concentrat pentru solutie perfuzabila 4 mg/5 ml
novartis pharma ag - acid zoledronicum - concentrat pentru solutie perfuzabila - 4 mg/5 ml